Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 11/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7872100 | 1.00 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23749683 | 1.00 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL9303984 | 0.86 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL9303991 | 0.86 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL1372203 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL17616112 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL3018246 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL27426180 | 0.83 | CYP2D6 (0.63) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL5198000 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL25270811 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | claimed |
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| EP-4655292-A1 | NEW COMPOUNDS FOR TREATING STREPTOCOCCUS INFECTIONS | Ab2 Therapeutics, S. L. (ES) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024156892-A1 | NEW COMPOUNDS FOR TREATING STREPTOCOCCUS INFECTIONS | ABAC Therapeutics, S.L. (ES) | 2024-08-02 | — | — | WO | disclosed |
| EP-4406945-A1 | NEW COMPOUNDS FOR TREATING STREPTOCOCCUS INFECTIONS | ABAC THERAPEUTICS, S.L. (ES) | 2024-07-31 | — | — | EP | disclosed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-6403648-B2 | RENIN INHIBITOR | G. D. SEARLE & CO. | 2002-06-11 | — | — | US | disclosed |
| US-4902706-A | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as antihypertensive agents | G. D. SEARLE & CO. (US) | 1990-02-20 | — | — | US | disclosed |
| US-4900746-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1990-02-13 | — | — | US | disclosed |
| WO-1990000050-A1 | AMINOALKYLAMINOCARBONYL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| WO-1990000052-A1 | POLY(AMINOALKYL)AMINOCARBONYL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| WO-1990000051-A1 | ETHEREAL N-TERMINAL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| EP-0349922-A2 | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0349921-A2 | Etheral n-terminal aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | disclosed |
| US-4877785-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1989-10-31 | — | — | US | disclosed |
| EP-0310072-A2 | Non-peptidyl beta-succinamidoacyl aminodiols as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | CA1 105/4885CA2 2648/4885CA7 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.